publication date: Sep. 29, 2017
Issue 36 - Sep. 29, 2017
To access this members-only content, please log in.
If you're not a subscriber why not join today?
If you believe you should be able to view this area but cannot log in, then please contact us and we will try to rectify this issue as soon as possible.
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.
  • Peter Pisters hits the right notes in town hall meeting at MD Anderson

    Returning to Houston for a town hall meeting at MD Anderson on Sept. 27, Peter Pisters, the institution’s freshly-appointed president, hit every note a guy in his position needed to hit: baseball, football, shared values, shared governance, book clubs, reminiscences on growing up nerdy in Canada, the story of how he met his wife, anecdotes from taking care of MD Anderson patients during Hurricane Rita.

    He brought with him a decades-old Grundig radio he used while taking care of MD Anderson patients during the 2005 Hurricane Rita, pictures of cute children and adorable dogs, but no notes—the talk just flowed, flawlessly, organically.

  • In draft, USPSTF recommends screening with hrHPV without cytology

    To detect high-grade precancerious cervical lesions and cervical cancer, women ages 30 to 65 may no longer need to rely on co-testing, and can choose to either screen for high-risk human papillomavirus types or undergo cervical cytology, according to a recent draft recommendation released by the U.S. Preventive Services Task Force.

    The draft statement, which is open for public comment through Oct. 9, recommends screening for cervical cancer every three years with cervical cytology alone in women ages 21 to 29. For women ages 30 to 65, USPSTF recommends either screening every three years with cervical cytology alone, or every five years with hrHPV testing alone.

  • Lowy & Schiller at the Lasker Awards: The paradox of disease prevention, and how some scientists rise above their peers

    Douglas Lowy and John Schiller received the 2017 Lasker-DeBakey Clinical Medical Research Award on Sept. 15 for research that led to development of the human papillomavirus vaccine.

    Lowy, who is completing his stint as the NCI acting director, becomes the first sitting head of the institute—permanent or acting—to win the award, which is described as America’s Nobel Prize (The Cancer Letter, Sept. 8).

     

  • Guest Editorial

    A costly “rebranding” of an old drug comes with a 700% price increase 

    Funaro is a resident at Duke Pharmacy, Friedman is the James B. Powell Professor of Pediatric Oncology at Duke, and Weant is a clinical pharmacist in neuro-oncology at Duke Pharmacy.

    Drug shortages, exorbitant medication costs, and price gouging tactics are facets of the American healthcare system that most providers have become all too familiar with in recent years. Unfortunately, oncology is no exception. Given the critical nature of the diseases they treat, chemotherapy agents, no matter how old, are particularly subject to these large and arbitrary price increases.

  • In Brief

    • CancerCare expands financial assistance for patients affected by hurricanes
    • Research!America to honor chair emeritus John Edward Porter and medical and health research advocacy leaders
    • Fox Chase Cancer Center receives gift to establish pancreatic cancer institute
    • Linus Chuang named chairman of obstetrics and gynecology at Western Connecticut Health Network
  • Drugs and Targets

    • FDA approves Verzenio for advanced or metastatic breast cancers
    • First anti-PD-1 therapy approved for advanced gastric adenocarcinoma
    • Amgen and AbbVie agree to settlement allowing commercialization of Amgevita
    • FDA approves new label for Sun Pharma’s Odomzo for sustained duration of response in treatment of basal cell carcinoma

Copyright (c) 2017 The Cancer Letter Inc.